Cochrane · systematic review · CD010389
Imiquimod for anogenital warts in non‐immunocompromised adults
Grillo‐Ardila, CF, Angel‐Müller, E, Salazar‐Díaz, LC, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Sexually Transmitted InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
17
current version
GRADE rated
17
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 12 · 70.6%Low 5 · 29.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Imiquimod compared to placebo for anogenital warts in non‐immunocompromised adults
Population: AGW in non‐immunocompromised adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete clearance Imiquimod vs placebo | RR 4.03 [2.03, 7.99] | 6 studies · 1294 participants | Very low Downgraded: risk of bias |
Partial clearance Imiquimod vs placebo | RR 2.57 [2.05, 3.21] | 6 studies · 1082 participants | Very low Downgraded: risk of bias |
Recurrence during Imiquimod vs placebo | RR 2.76 [0.7, 10.91] | 4 studies · 286 participants | Very low Downgraded: risk of bias, inconsistency |
Appearance of new warts during treatment Imiquimod vs placebo | RR 0.76 [0.58, 1] | 3 studies · 671 participants | Very low Downgraded: risk of bias, inconsistency |
Any local reactions during therapy Imiquimod vs placebo | RR 1.73 [1.18, 2.53] | 5 studies · 1225 participants | Very low Downgraded: risk of bias, inconsistency |
Any systemic reactions during therapy Imiquimod vs placebo | RR 0.91 [0.63, 1.32] | 2 studies · 313 participants | Low Downgraded: risk of bias, inconsistency |
Pain during therapy Imiquimod vs placebo | RR 11.84 [3.36, 41.63] | 2 studies · 804 participants | Low Downgraded: risk of bias, inconsistency |
Imiquimod compared to any other patient‐applied treatment for anogenital warts in non‐immunocompromised adults
Population: AGW in non‐immunocompromised adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete clearance Imiquimod vs any other patient‐applied treatment | RR 1.09 [0.8, 1.48] | 2 studies · 105 participants | Very low |
Partial clearance Imiquimod vs any other patient‐applied treatment | RR 0.77 [0.4, 1.47] | 1 study · 60 participants | Low |
Recurrence during Imiquimod vs any other patient‐applied treatment | RR 0.49 [0.21, 1.11] | 1 study · 30 participants | Low |
Any local reactions during therapy Imiquimod vs any other patient‐applied treatment | RR 1.24 [1, 1.54] | 2 studies · 105 participants | Very low |
Any systemic reactions during therapy Imiquimod vs any other patient‐applied treatment | RR 0.3 [0.09, 0.98] | 1 study · 60 participants | Low |
Imiquimod compared to any other provider‐administered treatment for anogenital warts in non‐immunocompromised adults
Population: AGW in non‐immunocompromised adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete clearance Imiquimod vs any other provider‐administered treatment | RR 0.84 [0.56, 1.28] | 2 studies · 335 participants | Very low Downgraded: inconsistency |
Recurrence during Imiquimod vs any other provider‐administered treatment | RR 0.24 [0.1, 0.56] | 1 study · 192 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Recurrence during Imiquimod vs any other provider‐administered treatment | RR 0.71 [0.4, 1.25] | 1 study · 53 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Pain during therapy Imiquimod vs any other provider‐administered treatment | RR 0.3 [0.17, 0.54] | 1 study · 80 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Any local reactions during therapy Imiquimod vs any other provider‐administered treatment | RR 0.55 [0.4, 0.74] | 1 study · 80 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |